linjc16/ctgov huggingface dataset:
Comparison of N-butyl-cyanoacrylate and Micro Parti-cles Effect in Inducing Liver Hypertrophy After PVE

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare hypertrophy of the FLR after PVE with microparticles to hypertrophy after PVE with cyanoacrylate in a material large enough to answer the study question. In addition, other factors that may influence the degree of hypertrophy will be evaluated in a multivariable analysis. The hypothesis is: PVE with cyanoacrylate is superior to PVE with microparticles in terms of FLR hy-pertrophy.

Detailed Description
-----------------
With expansion of indications for major liver surgery, portal vein embolization (PVE) is increasingly used in order to induce hypertrophy of the future liver remnant (FLR). De-spite vide variety of materials available to occlude the portal veins the most commonly used are cyanoacrylate and microparticles/spheres. Earlier studies have failed to show superiority of one over the other in terms of hypertrophy of the FLR while PVE with cy-anoacrylate seems to be less time consuming. Two small previous studies from single centers have shown greater growth by cyanoacrylate compared to particles (1) with 90 included patients and the second study with 34 included patients (2), but larger reviews have failed (3). Cyanoacrylate might give a more robust FLR hypertrophy (4) . The main problem in evaluating previous studies has been the large heterogeneity and the often poorly described study populations.

Official Title
-----------------
N-butyl-cyanoacrylate Glue Versus Micro Particles and the Effect on Inducing Liver Hypertrophy After Portal Vein Embolization- a Retrospective Swedish Multicenter Study

Conditions
-----------------
Portal Vein Embolization, Liver, Hypertrophy

Intervention / Treatment
-----------------
* Procedure: Portal vein embolization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years old. Planned for portal vein embolization. - Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NBCA<br>Patients that recieved portal vein embolization with n-butyl-cyanoacrylate glue. | Procedure: Portal vein embolization<br>* Portal vein emboliazation with either NBCA or micro particles.<br>|
| Particles<br>Patients that recieved portal vein embolization with micro particles. | Procedure: Portal vein embolization<br>* Portal vein emboliazation with either NBCA or micro particles.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FLR hypertrophy |  | Spring 2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Degree of hypertrophy |  | Spring 2023 | 
| Kinetic growth rate |  | Spring 2023 |
Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone

Study Overview
=================
Brief Summary
-----------------
A follow-up study on the randomized, controlled, double-blind HIGH: low study. We will examine the participants from the HIGH: low study min. 6 months after finishing the HIGH: low study. We will look at the parameters: quality of life, sugar-metabolism, fat-metabolism, fat-redistribution and cytokines. The study will use the participants control visit, and the only additional examination will be the danish MOS-HIV questionnaire.

Official Title
-----------------
Follow-up on the HIGH: Low Study - the Longterm Effect of Growth Hormone

Conditions
-----------------
HIV Infections, HIV-Associated Lipodystrophy Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 18 years of age Participated in and completed the HIGH: low study informed consent signed Exclusion Criteria: Patient stopped at Hvidovre Hospital, or didn't finish the HIGH: low study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| H, NH<br>HIV positive patients with and without lipodystrophy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  | 6 months follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolism |  | 6 months follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
growth hormone, quality of life, fat redistribution, sugar metabolism, fat metabolism, cytokines
Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma.

Study Overview
=================
Brief Summary
-----------------
Diffuse infiltrating pneumonia (DIP) is a severe complication of systemic sclerosis and one of the leading cause of death in this condition. The main objective of this study is to prospectively describe the evolution of DIP overtime and to find prognosis factors.

Official Title
-----------------
Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma and Analysis of Associated Factors.

Conditions
-----------------
Systemic Sclerosis

Intervention / Treatment
-----------------
* Other: lung function tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: systemic sclerosis Diffuse Infiltrating Pneumonia Exclusion Criteria: infection other lung diseases non French native

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with systemic sclerosis<br> | Other: lung function tests<br>* Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| composite criteria: forced vital capacity and CO diffusing capacity | Degradation of forced vital capacity (FVC) ≥10% and / or DLCO ≥15% of initial values at prospective follow-up at 24 months. | At 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| composite criteria: forced vital capacity and CO diffusing capacity | Degradation of forced vital capacity (FVC) ≥10% and / or DLCO ≥15% of initial values at prospective follow-up at 12 months. | At 12 months |
The Intra-Aortic Balloon Pumps Insertion Registry on Behalf of the Groupe Des Angioplasticiens de la Région Ouest

Study Overview
=================
Brief Summary
-----------------
Intra-aortic Balloon Pumps (IABP) have been used for roughly 50 years in Critical Care Units, Intensive Care Units, Cath labs as a way to improve systemic and coronary circulation in patients in cardiogenic shock (CS) or at high risk situation as mechanical complications stemming from myocardial infarction (MI), critical coronary stenosis, high-risk PCI, etc. Several papers recently questioned the relevance of this assistance device - namely the IABP-SHOCK II trial in CS and the CRISP-AMI trial in anterior MI without CS - resulting in the downgrading of the recommendation standards of the IABP by medical societies.

Official Title
-----------------
The Intra-Aortic Balloon Pumps Insertion Registry on Behalf of the Groupe Des Angioplasticiens de la Région Ouest

Conditions
-----------------
Interventional Cardiology

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females at least of 18 of age; Undergoing IABP treatment ; Subject, relatives or legal guardian signified their non-opposition to participate in the study Exclusion Criteria: - IABP insertion in immediate post-intervention period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IABP insertion rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cardiogenic shock | IABP indications | 1 year | 
| Number of mechanical complication of acute coronary syndrome | IABP indications | 1 year | 
| Number of myocardial infarction not shocked | IABP indications | 1 year | 
| Number of other indications | IABP indications | 1 year | 
| Survival rate following IABP insertion |  | 1 year | 
| IABP-related complications rate and type |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intra-aortic Balloon Pumps, Registry
Leucine Supplementation in Young Subjects Undergoing Resistance Training

Study Overview
=================
Brief Summary
-----------------
Leucine supplementation could be useful to support muscle anabolism. This study aims to investigate the effects of leucine supplementation on muscle mass and muscle strength in young subjects undergoing resistance training.

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Dietary Supplement: Leucine
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: training experience > 12 months no previous use of anabolic steroids no diagnosed diseases or injuries at the time of recruitment one-maximum repetition strength (1-RM) in leg press ≥ 3.5 and ≤ 5.0 times the body weight Exclusion Criteria: use of creatine or beta-alanine supplements for the last 3 months use of protein or aminoacids supplements for the last 1 month engagement in specific dietary restrictions engagement in competitive sports

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Leucine<br>Leucine supplementation (10 g/d) | Dietary Supplement: Leucine<br> <br> |
| Placebo Comparator: Placebo<br>Placebo supplementation (alanine, 10 g/d) | Dietary Supplement: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle cross-sectional area | B-mode ultrasound | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle strength | One repetition maximum (1RM) on 45º leg press machine and Muscular Endurance Test on 45º leg press machine | 12 weeks |
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.

Official Title
-----------------
A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration

Conditions
-----------------
Cardiovascular Disease, Ischemic Heart Disease

Intervention / Treatment
-----------------
* Drug: apadenoson


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Have known or suspected heart disease Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days. Weigh between 88 and 250 lbs. Exclusion Criteria: Allergic reaction to Technetium Tc99m Sestamibi or any of its components History of asthma or lung disease Ingestion of caffeinated substances within 12 hours prior to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: apadenoson|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurements of Technetium Tc99m Sestamibi activity will be obtained from various regions of the body at the end of the study to determine optimal imaging times. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A comparison of adverse events will be conducted at the end of the study to assess safety. |  |  |
Acute Gastroenteritis: Development of PCR Analysis and Algorithm for Fast Clarification of Isolation Indication

Study Overview
=================
Brief Summary
-----------------
Isolation of contagious patients is expensive, requires more caregiver time, most of the patients perceive isolation as a mental strain and it has been shown that the level of care and observation is lower than in a normal ward. But isolation of contagious patients is necessary to protect other patients, hospital staff and relatives to prevent spreading of infection and, in worst case out-break. There are different isolation regimes available depending on causative agent and mode of transmission. A community-acquired acute gastroenteritis (GE) is most often caused by Norovirus while a hospital-acquired acute GE is often caused by toxin producing Clostridium difficile. Patients infected with Norovirus or Clostridium difficile have to be isolated in single rooms with strict contact precautions. Patients infected with acute GE caused by other pathogens can be isolated in a multi-bed room if there is a private toilet. However, at the time of arrival to hospital it is not known if the patient is contagious. The indication of isolation has to be made based of a clinical evaluation in risk of isolating to few or too many patients. Aim of the study: To identify anamnestic, clinical and paraclinical variables that can be used as indicators of the aetiology of infectious GE, thus giving an indication for isolation. To clinically evaluate a combined RNA (Norovirus) and DNA (Clostridium difficile) fast PCR analysis test to identify infectious GE compared to gold standard methods.

Official Title
-----------------
Acute Gastroenteritis: Development of PCR Analysis and Algorithm/Criteria for Fast Clarification of Isolation Indication

Conditions
-----------------
Gastroenteritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acutely admitted more than three Loose stool, or lest than three Loose stools and vomiting within the last three weeks Exclusion Criteria: age under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| faeces examination for norovirus and clostridium difficile bacteria |  | one week |
Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics

Study Overview
=================
Brief Summary
-----------------
This is a Phase 3: Efficacy Study for AMARGOL® a phytomedicine used for asymptomatic digestive complaints.

Detailed Description
-----------------
This study will be performed for proving the efficacy of AMARGOL®, a phytomedicine product, under the Brazilian law for registration and revalidation RDC 14/2010. AMARGOL® indications are for non specific digestive complaints as laxative and anti-dyspeptic. Is a mixture of 7 plant extracts: Aloe ferox, Angelica archangelica, Alpinia officinarum, Cinnamomum zeylanicum, Gentiana lutea, Commiphora myrrh and Rheum palmatum. Placebo controlled test

Official Title
-----------------
Phase III - Efficacy Study of AMARGOL - Phytomedicine on Therapeutics

Conditions
-----------------
Digestive System Disorders

Intervention / Treatment
-----------------
* Drug: AMARGOL®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-45 years old 65-85 Kg healthy volunteers Exclusion Criteria: chronic dyspeptics illness chronic congestive cardiac problems pulmonary problems diabetes, thyroid problems pregnancy bowel syndrome hemorrhoids colitis allergies for any formula components.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: AMARGOL<br>per oral solution 40 mL single dose | Drug: AMARGOL®<br>* per oral solution, 40 mL single dose<br>* Other names: Herbal Extracts Mixture;|
| Placebo Comparator: Vehicle without active principles<br>per oral solution 40 mL single dose | Drug: AMARGOL®<br>* per oral solution, 40 mL single dose<br>* Other names: Herbal Extracts Mixture;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS - visual analogue scale | Single dose 40mL AMARGOL 20 minutes before Dinner - strong meal | 24h | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyspepsia, Flatulence, Aerophagia, Constipation
Fractional Exhaled Nitric Oxide (FeNO) Result Prediction Factors in Children With Allergic Diseases

Study Overview
=================
Brief Summary
-----------------
In about 800 children with allergic diseases (asthma, allergic rhinitis, atopic dermatitis) the investigators will retrospectively and cross-sectionally analyze the influence/correlation of diagnosis, treatment methods, allergy status (skin prick test results), lung function tests results on/with the concentration of nitric oxide in exhaled breath.

Detailed Description
-----------------
In about 800 children with allergic diseases from our Outpatient Clinic (asthma, allergic rhinitis, atopic dermatitis) we will retrospectively and cross-sectionally analyse the influence/correlation of diagnosis, treatment methods, allergy status (skin prick test results), lung function tests results on/with the concentration of nitric oxide in exhaled breath.

Official Title
-----------------
FeNO Result Prediction Factors in Children With Allergic Diseases

Conditions
-----------------
Asthma, Allergic Rhinitis, Atopic Dermatitis

Intervention / Treatment
-----------------
* Procedure: measurements of lung function tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with asthma (allergic), and/or allergic rhinitis and/or atopic dermatitis Exclusion Criteria: Other chronic diseases Asthma exacerbation Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Schoolchildren with asthma.<br>Schoolchildren with asthma. | Procedure: measurements of lung function tests<br>* Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test<br>* Other names: Exercise provocation test treadmill- Kettler;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of nitric oxide in exhaled breath. |  | 1-4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Allergic Rhinitis, Atopic Dermatitis, Children, lung function, skin prick tests, FeNO
SABINA INTERNATIONAL

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to describe the prescribing pattern of the different types of medications which are used to treat asthma, across multiple countries.

Official Title
-----------------
A Multi-country Study on the Prescription Patterns of Short Acting Beta-2 Agonist (SABA) and Its Potential Effects on Asthma Control: A Cross-Sectional Study on SABA Use in Asthma

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients ≥12 years-old Documented diagnosis with Asthma as per medical records. Have had ≥3 consultations with the HCP at study start date After full explanation, a patient or legal guardian must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study. Exclusion Criteria: Patient with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory disease different from Asthma. An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The main outcome will be a categorisation of SABA prescription in asthma patients. | Mild asthma patients will be categorised into 5 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date (initial exposure window): No prescriptions for asthma inhalers Appropriate SABA prescription with no ICS Appropriate SABA prescription with ICS SABA over-prescription with no ICS SABA over-prescription with ICS Moderate/severe asthma patients will be categorised into 2 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date: Appropriate SABA prescription on top of maintenance therapy SABA over-prescription on top of maintenance therapy | 12 months retrospective from index date |